Arena is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs.
Our internally discovered and developed drug, BELVIQ® (lorcaserin HCl), is approved by the US Food and Drug Administration and now available in the United States. Following are links to certain additional information:
We have granted exclusive BELVIQ marketing and distribution rights to Eisai Inc. for most of North and South America, to Ildong Pharmaceutical Co., Ltd., for South Korea and to CY Biotech Company Ltd. for Taiwan. We plan to enter into additional collaborations to commercialize BELVIQ outside of these territories.
We are exploring BELVIQ’s therapeutic potential in combination with other drugs and for other indications.
We are utilizing our validated discovery and development approach to selectively advance our pipeline of internally discovered, oral drug candidates.